Identifying Moraxella osloensis: Lab Techniques and Characteristics

Moraxella osloensis is a gram-negative bacterium that lives quietly on human skin and mucous membranes but can cause serious infections in vulnerable patients. Pinning down its identity in the clinical microbiology lab is frustratingly difficult: conventional biochemical test systems routinely fail to distinguish it from closely related species. Reliable identification typically requires molecular methods such as 16S rRNA gene sequencing or proteomic tools like MALDI-TOF mass spectrometry, and the organism’s understated biochemical profile is a big reason why it has historically been underreported in clinical settings.

Basic Morphology and Growth

Under the microscope, M. osloensis appears as a gram-negative rod or coccobacillus, though its shape can vary depending on culture conditions and age of the colony. In at least one well-documented clinical case involving a catheter-related bloodstream infection, blood cultures grew gram-negative bacilli that were aerobic, oxidase-positive, and catalase-positive.¹ Those two enzyme reactions, oxidase and catalase, are among the first screening results a lab technician sees. They narrow the field but do not get you to a species name. Many other Moraxella species and related organisms share the same profile.

On standard blood agar plates, M. osloensis colonies tend to be small, smooth, and non-pigmented after overnight incubation at 35–37 °C. The organism grows aerobically and does not require enriched CO₂ atmospheres, though growth can be slow compared to more robust gram-negative pathogens. It does not ferment carbohydrates, which places it in the nonfermentative gram-negative group alongside organisms like Acinetobacter and Pseudomonas. That grouping is clinically relevant because nonfermenters as a class are already harder to identify with routine automated systems, and M. osloensis sits at the more cryptic end of that spectrum.

Why Conventional Identification Systems Struggle

If you run an M. osloensis isolate through a standard commercial identification panel, there is a real chance it will come back labeled as the wrong species or simply as “Moraxella species” with no further resolution. A case series describing three patients with M. osloensis meningitis reported that species-level identification was impossible using both conventional and commercial phenotypic tests.² A separate case of bacteremia documented the same problem: the BD Phoenix automated system could detect that the organism was a Moraxella but could not resolve it to the species level.³

The root of the difficulty is that M. osloensis shares phenotypic characteristics with several sibling species. It is asaccharolytic (does not break down sugars), does not produce indole, and lacks most of the dramatic enzymatic reactions that commercial panels rely on to differentiate organisms. When your identification scheme depends on a pattern of positive and negative reactions, an organism that is negative for almost everything is essentially invisible against a backdrop of other inert organisms. The result is that labs without access to advanced tools may report a vague genus-level identification, potentially delaying targeted treatment.

MALDI-TOF Mass Spectrometry

The introduction of MALDI-TOF MS into routine clinical microbiology labs has been transformative for organisms like M. osloensis. The technique works by ionizing bacterial proteins from a colony smear and generating a spectral fingerprint that is matched against a reference database. It is fast, typically delivering a species-level result within minutes of applying the colony to the target plate, and it costs very little per test once the instrument is in place.

In the bacteremia case where the BD Phoenix system failed, MALDI-TOF MS (using the Bruker Biotyper platform) successfully identified the isolate as M. osloensis. That identification was subsequently confirmed by 16S rRNA gene sequencing.³ A separate review described MALDI-TOF MS as a tool for rapid, accurate, and cost-effective identification of cultured bacteria and fungi, noting that it was the primary method used to identify M. osloensis in their reported case before molecular confirmation.³

One important caveat: MALDI-TOF accuracy depends on the quality and completeness of the reference database loaded onto the instrument. Older or smaller databases may not include M. osloensis spectra at all, or may include only a single reference strain, which can lead to low-confidence scores or misidentification. Labs that encounter unusual nonfermenters should ensure their MALDI-TOF database is current, especially for the Moraxella genus where multiple species cluster closely together.

16S rRNA Gene Sequencing as the Reference Standard

When absolute certainty is needed, 16S rRNA gene sequencing remains the most reliable method for species-level identification of M. osloensis. The approach involves amplifying a conserved ribosomal RNA gene from the isolate and comparing its sequence against public databases. Investigators in both the meningitis case series and the bacteremia report used 16S rRNA sequencing as the confirmatory step after other methods either failed or provided only a preliminary answer.²

The drawback of sequencing is turnaround time and infrastructure. Even with modern platforms, the process takes hours to a day or more, and not every hospital lab has the equipment or expertise to run it in-house. Many send isolates to reference laboratories. For a critically ill patient, that delay matters, which is why MALDI-TOF has become the practical first-line tool and sequencing serves more as a confirmatory backstop or a research-grade identification method.

Genomic Features Worth Knowing

The complete genome of a multidrug-resistant M. osloensis strain (NP7), isolated from human skin, has been sequenced and provides a useful reference point for understanding the species. The chromosome is roughly 2.39 million base pairs with a G+C content of about 44%, encoding around 2,065 protein-coding genes. What makes this strain particularly interesting is that it carries seven plasmids totaling over 650,000 base pairs, with genes conferring resistance to beta-lactam and aminoglycoside antibiotics predicted to reside on one of those plasmids.⁴

The chromosome also harbors four ribosomal RNA operons, 47 tRNA genes, and three CRISPR arrays, with an additional CRISPR array on one of the plasmids.⁴ The presence of CRISPR systems suggests the organism has some capacity to defend itself against foreign DNA, such as phages. And the fact that resistance genes sit on transferable plasmids rather than the chromosome raises the question of how readily M. osloensis could share those genes with other bacteria in a mixed skin or hospital environment.

Intrinsic Colistin Resistance

One of the more scientifically significant findings about M. osloensis is that it carries an intrinsic colistin resistance determinant, designated ICR-Mo. Colistin is a last-resort antibiotic used against multidrug-resistant gram-negative infections, and the emergence and transfer of colistin resistance genes (particularly the MCR family) has been a major global health concern. ICR-Mo is a chromosomal gene related to the MCR family but is native to M. osloensis rather than acquired from another organism.

Experiments showed that ICR-Mo, when transferred into a susceptible E. coli host, allowed growth on plates containing up to 8 micrograms per milliliter of colistin, which is comparable to another known resistance determinant (EptA) but lower than the 16 micrograms per milliliter conferred by MCR-1.⁵ Point mutations in ICR-Mo’s zinc-binding residues completely abolished resistance. The concern is not so much that M. osloensis infections are themselves untreatable with colistin (infections by this species are rare), but rather that ICR-Mo could theoretically serve as a reservoir for colistin resistance genes that might eventually be mobilized to more dangerous pathogens. Whether that transfer actually occurs in nature at meaningful rates is still an open question, but it makes M. osloensis relevant to antimicrobial resistance surveillance even when it is not causing infections.

Where M. osloensis Causes Trouble Clinically

M. osloensis is part of the normal flora of human skin, mucous membranes, and the respiratory tract.⁶ Infections are uncommon, but when they occur, they tend to show up in people who are immunocompromised or have indwelling medical devices. A literature review cataloging reported cases found that M. osloensis has been implicated in bacteremia, central line-related bloodstream infections, endocarditis, meningitis, peritonitis, bone and joint infections, pneumonia, and eye infections including keratitis and postoperative infection from contaminated propofol.⁷

One notable case was an endocarditis in a patient without obvious immune deficiency, described as the first such report in Latin America.⁸ Cases like that one are reminders that while immunosuppression is the main predisposing factor, healthy individuals are not completely exempt. Whether M. osloensis is a genuine pathogen or merely a contaminant in a given blood culture is a clinical judgment call that depends on the number of positive bottles, the patient’s clinical picture, and whether alternative explanations exist. The identification difficulty described earlier compounds this problem: if the lab cannot tell you exactly what species grew, the clinician has less information to decide whether to treat.

Beyond the Clinic: Laundry Odor and Slug Biocontrol

M. osloensis has a surprisingly prominent life outside human infections. A Japanese study investigating the persistent musty smell in laundry, the kind that returns even after washing, identified M. osloensis as the primary bacterium responsible. The major malodor compound was identified as 4-methyl-3-hexenoic acid (4M3H), and the researchers confirmed that M. osloensis generates this compound in laundry fabrics.⁹ The study used morphological observation, biochemical tests, and phylogenetic analysis to confirm the species identity of the isolates, which is a useful reminder that traditional identification methods work better when the organism is being compared against a narrow panel of environmental suspects rather than the entire clinical universe of nonfermenters.

In agriculture, M. osloensis has an established role as a symbiont of the nematode Phasmarhabditis hermaphrodita, a parasite of slugs. The bacterium is carried in the nematode’s gut, and when the nematode infects a slug, M. osloensis is released into the slug’s body where it contributes to killing the host.¹⁰ This nematode-bacterium partnership is the basis of a commercial biological control product used against slugs in European agriculture. The fact that M. osloensis is pathogenic to invertebrates but typically harmless in immunocompetent humans is a useful illustration of how bacterial virulence is context-dependent.

There is also evidence that M. osloensis can degrade environmental pollutants. A study on bioremediation of phenanthrene, a polycyclic aromatic hydrocarbon found in contaminated soils, used a consortium of two bacteria: Bacillus subtilis to adsorb rare earth metal contaminants and M. osloensis (strain CFP312) to break down phenanthrene. The M. osloensis strain degraded phenanthrene effectively, although rare earth ions at certain concentrations inhibited its degradative activity.¹¹ These environmental capabilities hint at a metabolic versatility in M. osloensis that is not immediately obvious from its bland performance on clinical biochemical panels.

A Name Change on the Horizon

Taxonomists have recently proposed reclassifying M. osloensis out of the genus Moraxella entirely. A genomic analysis found that M. osloensis, along with M. boevrei and M. atlantae, clusters more closely with Faucicola mancuniensis than with the core Moraxella species. The proposal is to reassign all three species to the genus Faucicola.¹² If this reclassification gains wide acceptance, clinical labs will eventually need to update their databases, reference materials, and reporting practices. That may take years; taxonomic reclassifications in clinical microbiology tend to be adopted slowly, and many labs continue using older names long after formal changes are published. For the time being, anyone searching the literature should be aware that “Moraxella osloensis” and “Faucicola osloensis” may refer to the same organism depending on when the paper was written.

The reclassification also has practical implications for identification databases. MALDI-TOF reference libraries and 16S rRNA sequence databases will need updated entries reflecting the new genus assignment. During the transition period, labs may encounter discrepancies where an isolate matches M. osloensis in one database and Faucicola osloensis in another, which could confuse clinicians unfamiliar with the name change. Good laboratory practice will involve flagging these synonyms in reporting and ensuring that antimicrobial susceptibility interpretations carry over correctly regardless of which name is used.

Practical Identification Workflow

For a lab encountering a nonfermenting gram-negative coccobacillus that is oxidase-positive and catalase-positive but otherwise biochemically inert, a reasonable identification workflow looks like this:

Initial screening: Gram stain morphology, oxidase, catalase, and growth characteristics on blood agar and MacConkey agar narrow the field to nonfermentative gram-negatives. M. osloensis typically grows on blood agar but may show poor or no growth on MacConkey.
Automated phenotypic panels: Run if available, but expect genus-level identification at best. If the system returns “Moraxella species” without species resolution, do not treat that as a definitive answer.
MALDI-TOF MS: If the lab has access, this is the fastest route to a species name. A high-confidence score against an up-to-date database is usually sufficient for clinical decision-making.
16S rRNA sequencing: Reserve for cases where MALDI-TOF gives a low-confidence result, where the species identification has direct treatment implications, or where the isolate is being characterized for epidemiological or research purposes.

The key takeaway for bench microbiologists is to maintain a healthy skepticism of genus-only identifications for Moraxella isolates. In a patient with an indwelling catheter and signs of bloodstream infection, the difference between M. osloensis and a contaminant can drive antibiotic choices and decisions about device removal. When in doubt, escalate to MALDI-TOF or send the isolate for sequencing. A vague result is not a reassuring result.

Susceptibility Testing Considerations

Antimicrobial susceptibility testing for M. osloensis is not well standardized. The Clinical and Laboratory Standards Institute (CLSI) provides breakpoints for Moraxella catarrhalis, the most clinically prominent member of the genus, but M. osloensis is a different organism with different resistance profiles. Most clinical isolates reported in the literature have been susceptible to a broad range of antibiotics, including penicillins, cephalosporins, fluoroquinolones, and carbapenems. However, the existence of multidrug-resistant strains carrying plasmid-borne resistance genes, as documented in the NP7 genome, means susceptibility should never be assumed.⁴

The intrinsic colistin resistance conferred by ICR-Mo is worth flagging for reference laboratories that may encounter M. osloensis in surveillance screens for colistin-resistant gram-negatives. An isolate testing resistant to colistin is not necessarily carrying a transferable MCR gene; it may simply be expressing its native ICR-Mo determinant.⁵ Distinguishing intrinsic from acquired resistance has implications for infection control decisions and public health reporting, since acquired MCR genes in gram-negatives trigger different alarm bells than intrinsic chromosomal resistance in a commensal species.

1
PubMed Central. Moraxella osloensis: an unusual cause of central venous catheter infection in a cancer patient
2
PubMed Central. Three cases of Moraxella osloensis meningitis: a difficult experience in species identification and determination of clinical significance
3
The Brazilian Journal of Infectious Diseases. Bacteremia due to Moraxella osloensis: a case report and literature review
4
Korean Journal of Microbiology. Complete genome sequence of multidrug-resistant Moraxella osloensis NP7 with multiple plasmids isolated from human skin
5
PLOS Genetics. Defining ICR-Mo, an intrinsic colistin resistance determinant from Moraxella osloensis
6
PubMed Central. An unusual osteomyelitis caused by Moraxella osloensis: A case report
7
IDCases. Moraxella osloensis bacteremia, a case series and review of the literature
8
PubMed Central. Endocarditis Caused by Gram-Negative Moraxella osloensis in an Immunocompetent Patient: First Case Report in Latin America
9
PubMed Central. Moraxella species are primarily responsible for generating malodor in laundry
10
PubMed Central. Pathogenicity of Moraxella osloensis, a bacterium associated with the nematode Phasmarhabditis hermaphrodita, to the slug Deroceras reticulatum
11
PubMed. Synergistic effects of a functional bacterial consortium on enhancing phenanthrene biodegradation and counteracting rare earth biotoxicity in liquid and slurry systems
12
PubMed. Reclassification of Moraxella boevrei, M. osloensis and M. atlantae, into the genus Faucicola, and proposal of a new genus within the family Moraxellaceae, Lwoffella lincolnii gen. nov., comb. nov., to accommodate the divergent species Moraxella lincolnii